BINASCHI, MONICA
BINASCHI, MONICA
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
2023 Fiascarelli, Alessio; Merlino, Giuseppe; Capano, Stefania; Talucci, Simone; Bisignano, Diego; Bressan, Alessandro; Bellarosa, Daniela; Carrisi, Corrado; Paoli, Alessandro; Bigioni, Mario; Tunici, Patrizia; Irrissuto, Clelia; Salerno, Massimiliano; Arribas, Joaquin; de Stanchina, Elisa; Scaltriti, Maurizio; Binaschi, Monica
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 Bardia, Aditya; Cortés, Javier; Bidard, François-Clément; Neven, Patrick; Garcia-Sáenz, José; Aftimos, Phillipe; O'Shaughnessy, Joyce; Lu, Janice; Tonini, Giulia; Scartoni, Simona; Paoli, Alessandro; Binaschi, Monica; Wasserman, Tomer; Kaklamani, Virginia
MEN1309/OBT076, a first-in-class antibody–drug conjugate targeting CD205 in solid tumors
2019 Merlino, G.; Fiascarelli, A.; Bigioni, M.; Bressan, A.; Carrisi, C.; Bellarosa, D.; Salerno, M.; Bugianesi, R.; Manno, R.; Morales, C. B.; Arribas, J.; Dusek, R. L.; Ackroyd, J. E.; Pham, P. H.; Awdew, R.; Aud, D.; Trang, M.; Lynch, C. M.; Terrett, J.; Wilson, K. E.; Rohlff, C.; Manzini, S.; Pellacani, A.; Binaschi, M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer | 2023 | Fiascarelli, Alessio; Merlino, Giuseppe; Capano, Stefania; Talucci, Simone; Bisignano, Diego; Bressan, Alessandro; Bellarosa, Daniela; Carrisi, Corrado; Paoli, Alessandro; Bigioni, Mario; Tunici, Patrizia; Irrissuto, Clelia; Salerno, Massimiliano; Arribas, Joaquin; de Stanchina, Elisa; Scaltriti, Maurizio; Binaschi, Monica | |
| Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups | 2024 | Bardia, Aditya; Cortés, Javier; Bidard, François-Clément; Neven, Patrick; Garcia-Sáenz, José; Aftimos, Phillipe; O'Shaughnessy, Joyce; Lu, Janice; Tonini, Giulia; Scartoni, Simona; Paoli, Alessandro; Binaschi, Monica; Wasserman, Tomer; Kaklamani, Virginia | |
| MEN1309/OBT076, a first-in-class antibody–drug conjugate targeting CD205 in solid tumors | 2019 | Merlino, G.; Fiascarelli, A.; Bigioni, M.; Bressan, A.; Carrisi, C.; Bellarosa, D.; Salerno, M.; Bugianesi, R.; Manno, R.; Morales, C. B.; Arribas, J.; Dusek, R. L.; Ackroyd, J. E.; Pham, P. H.; Awdew, R.; Aud, D.; Trang, M.; Lynch, C. M.; Terrett, J.; Wilson, K. E.; Rohlff, C.; Manzini, S.; Pellacani, A.; Binaschi, M. |